Cytek BioSciences, which provides cell analysis instruments for life science applications, raised $285 million by offering 16.7 million shares (30% secondary) at $17, within the range of $16 to $18. The offering contained 2.2 million more shares than anticipated.
Cytek Biosciences' core products are the Aurora and Northern Lights systems, which are full spectrum flow cytometers that deliver high-resolution cell analysis by using the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, also known as full spectrum profiling. As of March 31, 2021, the company has placed over 750 instruments to over 620 companies around the world, including pharmaceutical companies, over 125 biopharma companies, academic research centers, and clinical research organizations.
Cytek BioSciences plans to list on the Nasdaq under the symbol CTKB. Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen acted as joint bookrunners on the deal.
